The Evolving Field of ER-Positive Metastatic Breast Cancer Care

The Evolving Field of ER-Positive Metastatic Breast Cancer Care

In February 2015, the CDK 4/6-inhibitor Ibrance was approved by the FDA in combination with letrozole for the treatment of postmenopausal women with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as …

(Visited 1 times, 1 visits today)
6
Like
Save

Comments

Write a comment

*